A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers
Completed
This is a Phase 1, double-blind, randomized trial to evaluate the safety and immunogenicity of two heterologous and two homologous prime-boost regimens using MVA-BN(R)-Filo and Ad26.ZEBOV administered in different sequences at Days 1 and 29 in healthy adult subjects aged 18 - 45 years. The study will evaluate the 'omics (transcriptomics, proteomics, lipidomics, metabolomics), antibodies for immunogenicity, CMI, ADCC, and plasmablast responses to MVA-BN(R)-Filo and Ad26.ZEBOV vaccines. The primar... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
07/24/2025
Locations: Emory University School of Medicine, Atlanta, Georgia
Conditions: Ebola Disease, Marburg Disease
VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions
Completed
This phase II trial studies the use of human papillomavirus (HPV) deoxyribonucleic acid (DNA) plasmids therapeutic vaccine VGX-3100 (VGX-3100) and electroporation in treating patients with human immunodeficiency virus (HIV)-positive high-grade anal lesions. Vaccines made from DNA may help the body build an effective immune response to kill tumor cells. Electroporation helps pores in your body's cells take in the drug to strengthen your immune system's response. Giving VGX-3100 and electroporatio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Grady Health System, Atlanta, Georgia
Conditions: Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity, Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive
Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study
Active Not Recruiting
This study is a prospective, randomized clinical trial. During this study, pregnant women will be randomly assigned to receive IIV and mRNA COVID-19 vaccine either simultaneously or sequentially (7-14 days apart). All participants will receive an mRNA COVID-19 vaccine at Visit 1 (Day 1). Solicited local and systemic symptoms of reactogenicity will be assessed on day of visit for Visits 1 and 2 and daily during the 6 days following each visit using either electronic or paper symptoms diaries, de... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Emory University, Atlanta, Georgia +1 locations
Conditions: Birth Outcomes, Safety, Adverse Event Following Immunization
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
Completed
This is a pilot, prospective, randomized, open-label clinical trial. During the study, pregnant women will be randomized (1:1) to receive co-administration of a single intramuscular (IM) 0.5 mL dose of US-licensed inactivated influenza vaccine (IIV) and a single intramuscular (IM) 0.5 mL dose of US-licensed Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (Tdap) or sequential administration of the vaccines (IIV followed by Tdap \~ 21 days later). Vaccines will b... Read More
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
07/08/2025
Locations: Centers for Disease Control and Prevention, Atlanta, Georgia
Conditions: Pregnancy
Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)
Completed
The purpose of this study is to evaluate the concomitant and non-concomitant use of messenger ribonucleic acid (mRNA) mRNA-1273, the nucleoside-modified mRNA vaccine for active immunization to prevent coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), with a 23-valent pneumococcal polysaccharide vaccine (V110) for the prevention of pneumococcal disease, or a 15-valent pneumococcal conjugate vaccine (V114) indicated for the prevention of invasive... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/08/2025
Locations: Atlanta Center For Medical Research ( Site 0053), Atlanta, Georgia
Conditions: Pneumococcal Infection
CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults
Recruiting
This is a study of CDC-9 inactivated rotavirus vaccine (IRV) microneedle patch (MNP) for intradermal administration in healthy adults aged 18 to 45 years at two dose levels in a 3-dose series. The purpose is to determine if it is safe and if the recipient's immune system responds to the vaccine.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
07/01/2025
Locations: Emory Children's Center - Vaccine Research Clinic, Atlanta, Georgia
Conditions: Rotavirus Infections
CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults
Active Not Recruiting
This is a study of CDC-9 inactivated rotavirus vaccine (IRV) for intramuscular administration (IM) in healthy adults aged 18 to 45 years at two dose levels in a 3-dose series. The purpose is to determine if it is safe and if the recipient's immune system responds to the vaccine.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
06/30/2025
Locations: Emory Children's Center - Vaccine Research Clinic, Atlanta, Georgia
Conditions: Rotavirus Infections
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
Completed
The purpose of this study to evaluate the safety and immunogenicity of a 2-dose regimen of 9vHPV vaccine, where the first dose is administered concomitantly with a first dose of a 2-dose regimen of mRNA-1273 vaccine versus nonconcomitant administration of 9vHPV and mRNA-1273 vaccines in boys and girls 9 to 11 years of age.
Gender:
ALL
Ages:
Between 9 years and 11 years
Trial Updated:
06/30/2025
Locations: Atlanta Center for Medical Research ( Site 0055), Atlanta, Georgia +1 locations
Conditions: Papillomavirus Infections, Coronavirus Disease (COVID-19)
Durability of Vaccine Responses
Recruiting
The ability of the vaccines today to generate a long-lasting protection against infections varies greatly from one vaccine to another. The yellow fever vaccine (YF-17D) is one of the most successful vaccines ever developed, having been administered to over 600 million people globally. A single vaccination is known to induce durable protection over several decades. In contrast, the quadrivalent influenza vaccine (QIV) generates an immunity that wanes quickly with no long-lasting protection. Curre... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
06/26/2025
Locations: Emory University Hospital, Atlanta, Georgia +2 locations
Conditions: Vaccine Response
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age
Completed
The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1083 as compared with active control, co-administered licensed influenza and severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) vaccines, in 2 independent age-group sub-study cohorts, healthy adults 65 years and older (Cohort A) and healthy adults 50 to \<65 years of age (Cohort B).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/23/2025
Locations: AES - DRS - Synexus Clinical Research US, Inc. - Atlanta, Atlanta, Georgia +6 locations
Conditions: SARS-CoV-2, Influenza
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
Completed
This study includes 3 parts: Parts A, B, and C. The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Synexus Clinical Research US, Inc. - Atlanta, Atlanta, Georgia +4 locations
Conditions: Seasonal Influenza
A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years
Active Not Recruiting
The purpose of this study is to assess the reactogenicity, safety and immune response of various formulations of the RSV mRNA investigational vaccine administered in healthy participants 18-45 years of age.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
06/13/2025
Locations: GSK Investigational Site, Atlanta, Georgia
Conditions: Respiratory Syncytial Virus Infections